Current Molecular Pharmacology Joins as Supporting Journal for the 3rd Chemistry Application and Biomedicine Forum at Tianjin University
Published 11 December, 2025
The 3rd Chemistry Application and Biomedicine Forum, held from October 10 to 12, 2025, at Tianjin University, successfully convened experts from academia and industry to advance discussions on biomedical innovation. The forum also celebrated the 130th anniversary of the Tianjin University and the 25th anniversary of the university's School of Medicine, Department of Pharmaceuticals.Current Molecular Pharmacology (CMP) proudly served as a co-organizer of this prestigious event, alongside leading institutions and industry partners.
The forum gathered renowned researchers, pharmaceutical professionals, and innovators to explore the latest developments in drug development, chemical biology, and biomedical technologies. Topics ranged from novel drug mechanisms and AI-driven pharmacology to glycoscience and targeted therapeutics. CMP’s participation reflects its ongoing commitment to promoting high-quality research in molecular pharmacology.
CMP's presence underscored its commitment to translating cutting-edge mechanistic research into tomorrow’s therapies. As an open-access journal indexed in SCIE, PubMed/MEDLINE, Scopus and Google Scholar, CMP disseminates rigorous studies on novel drug action, innovative pharmacological technologies and multi-omics applications. The 2024 edition carries an Impact Factor of 2.9, a CiteScore of 5.5, and ranks in the Q2 quadrant of Pharmacology & Pharmacy (150/352) while holding a stable Q3 position in Biochemistry & Molecular Biology (182/319).
Featuring presentations on topics from targeted protein degradation to AI in drug discovery, the forum highlighted the interdisciplinary collaboration that drives the field forward. CMP is committed to supporting such essential scientific dialogue and looks forward to contributing to future initiatives that expand the frontiers of pharmacology.